Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Carl Arneson"'
Autor:
Victor F. Tapson, Zhi-Cheng Jing, Kai-Feng Xu, Lei Pan, Jeremy Feldman, David G. Kiely, Eugene Kotlyar, C. Shane McSwain, Kevin Laliberte, Carl Arneson, Lewis J. Rubin
Publikováno v:
Chest. 144:952-958
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4653288186fafb239c1114c2bf05f79a
https://doi.org/10.1378/chest.12-2875
https://doi.org/10.1378/chest.12-2875
Autor:
Shelley M. Shapiro, Victor F. Tapson, Kevin Laliberte, Roblee P Allen, Robert P. Frantz, Anne Keogh, Carl Arneson, Fernando Torres, Jeffrey Sigman, David B. Badesch, Adaani E. Frost, Fiona Kermeen, Nazzareno Galiè
Publikováno v:
Chest. 142:1383-1390
Background Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a sustained-release oral formulation of treprostinil, was studied to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::269efa53af0b61fa4a502b081446825b
https://doi.org/10.1378/chest.11-2212
https://doi.org/10.1378/chest.11-2212
Publikováno v:
The Journal of Heart and Lung Transplantation. 30:982-989
Because of the challenges associated with conducting large survival studies of patients with pulmonary arterial hypertension (PAH), we analyzed the surrogate markers predictive of long-term survival in a large cohort of patients treated with subcutan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002ae9159b22c89df454914a6fbd7dec
https://doi.org/10.1016/j.healun.2011.03.011
https://doi.org/10.1016/j.healun.2011.03.011
Autor:
Carl Arneson, Somasundaram Shanmugasundaram, Leland Shapiro, Jagdish Hiremath, Cindy L. Vnencak-Jones, Gregory B. Pott, R. James White, Sudhakar Bangera, Keyur Parikh, Sadagopa Thanikachalam, Michael Wade
Publikováno v:
The Journal of Heart and Lung Transplantation. 29:137-149
Background Pulmonary arterial hypertension (PAH) remains a poorly understood and frequently lethal disease with few treatment options. Methods We conducted a placebo-controlled trial of intravenous treprostinil, a prostacyclin analog, in treatment-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1683a34cf310c65d4673e5ea6535b279
https://doi.org/10.1016/j.healun.2009.09.005
https://doi.org/10.1016/j.healun.2009.09.005
Autor:
Dianne L. Zwicke, Vallerie V. McLaughlin, C. Gregory Elliott, Carl Arneson, Ronald J. Oudiz, Shelley M. Shapiro, C. Shane McSwain, Robert Schilz, Michael Wade, Ray Benza, Nicholas S. Hill, James P. Staszewski, David Zaccardelli
Publikováno v:
The Journal of Clinical Pharmacology. 48:19-25
19 This study assessed the relationship between dose and plasma concentration following administration of treprostinil sodium infusion therapy in pulmonary arterial hypertension patients. This was a multicenter, open-label, multiple-cohort, steady-st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fcfa4830e2229a25eabb34a68f766d
https://doi.org/10.1177/0091270007309708
https://doi.org/10.1177/0091270007309708
Autor:
Allen A. Lai, Thomas L. Hunt, F. Jo Baker, Michael Wade, Carl Arneson, Wayne DellaMaestra, Robert Roscigno
Publikováno v:
The Journal of Clinical Pharmacology. 44:503-509
The objective of this study was to assess the pharmacokinetics and safety of treprostinil sodium administered as a 28-day continuous subcutaneous infusion at escalating infusion rates of 2.5 to 15 ng/kg/min in normal subjects. Fourteen healthy adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f967f70ec80fc8b08e5d4084a9f1b8
https://doi.org/10.1177/0091270004264638
https://doi.org/10.1177/0091270004264638
There are limited data on the management of pulmonary arterial hypertension (PAH) in the elderly; therefore, this analysis compared the safety and efficacy of tadalafil between patients ≥65 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d70675631df4a99ce686d954febe38f
https://europepmc.org/articles/PMC4070753/
https://europepmc.org/articles/PMC4070753/
Autor:
Carlos Jerjes-Sánchez, Kevin Laliberte, Tomás Pulido, Keyur Parikh, Lewis J. Rubin, Zhi-Cheng Jing, Adam Torbicki, Carl Arneson, R. James White, Roblee P Allen, Kai Feng Xu, David Yehle
Publikováno v:
Circulation. 127(5)
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9326587299312e0adaf2ce15ad920661
https://pubmed.ncbi.nlm.nih.gov/23358265
https://pubmed.ncbi.nlm.nih.gov/23358265
Autor:
Erika B. Rosenzweig, S. Karl Gotzkowsky, Hubert Chen, Carl Arneson, Robert C. Bourge, Andrew Nelsen
Publikováno v:
Health and Quality of Life Outcomes
Background Patient treatment satisfaction is likely to be a highly relevant outcome measure in pulmonary arterial hypertension (PAH), a condition for which the benefits of treatment must be weighed against frequent, undesirable side effects, inconven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e7fe6cfa550ee73500ace33511664b
Autor:
Victor F, Tapson, Fernando, Torres, Fiona, Kermeen, Anne M, Keogh, Roblee P, Allen, Robert P, Frantz, David B, Badesch, Adaani E, Frost, Shelley M, Shapiro, Kevin, Laliberte, Jeffrey, Sigman, Carl, Arneson, Nazzareno, Galiè
Publikováno v:
Chest. 142(6)
Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations. This study assessed the efficacy and safety of bid oral sustained-release treprostinil in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1dea5d56172045b55fcf168ff214c70f
https://pubmed.ncbi.nlm.nih.gov/23208324
https://pubmed.ncbi.nlm.nih.gov/23208324